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Abstract
The vast personal and economic burden of mood disorders is largely caused by their under- and misdiagnosis, which
is associated with ineffective treatment and worsening of outcomes. Here, we aimed to develop a diagnostic
algorithm, based on an online questionnaire and blood biomarker data, to reduce the misdiagnosis of bipolar disorder
(BD) as major depressive disorder (MDD). Individuals with depressive symptoms (Patient Health Questionnaire-9 score
≥5) aged 18–45 years were recruited online. After completing a purpose-built online mental health questionnaire,
eligible participants provided dried blood spot samples for biomarker analysis and underwent the World Health
Organization World Mental Health Composite International Diagnostic Interview via telephone, to establish their
mental health diagnosis. Extreme Gradient Boosting and nested cross-validation were used to train and validate
diagnostic models differentiating BD from MDD in participants who self-reported a current MDD diagnosis. Mean test
area under the receiver operating characteristic curve (AUROC) for separating participants with BD diagnosed as MDD
(N= 126) from those with correct MDD diagnosis (N= 187) was 0.92 (95% CI: 0.86–0.97). Core predictors included
elevated mood, grandiosity, talkativeness, recklessness and risky behaviour. Additional validation in participants with
no previous mood disorder diagnosis showed AUROCs of 0.89 (0.86–0.91) and 0.90 (0.87–0.91) for separating newly
diagnosed BD (N= 98) from MDD (N= 112) and subclinical low mood (N= 120), respectively. Validation in
participants with a previous diagnosis of BD (N= 45) demonstrated sensitivity of 0.86 (0.57–0.96). The diagnostic
algorithm accurately identified patients with BD in various clinical scenarios, and could help expedite accurate clinical
diagnosis and treatment of BD.
Introduction
Mood disorders are devastating psychiatric conditions
which impose substantial burdens to individuals, health-
care systems and economies. Major depressive disorder
(MDD) and bipolar disorder (BD) are two of the most
common mood disorders and affect ~16.6% and 3.9% of
the global population, respectively, throughout their life-
time1. In 2017 alone, about 163 million people (2.1% of
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global population) suffered from MDD and 46 million
(0.6%) were affected by BD, accounting for 32.8 million
years lived with disability (YLDs) in the case of MDD and
9.3 million YLDs for BD2. These numbers have been
steadily increasing since the 1990s2 and both conditions
are currently among the 20 leading causes of disability
worldwide, with MDD ranked 2nd and BD 17th3. In
England, the direct economic burden of managing mood
disorders, encompassing healthcare, informal care and
justice system services, is estimated at £1.68 billion
annually for depression and £1.64 billion for bipolar
spectrum disorders, while indirect costs associated with
lost work productivity amount to £5.82 billion and £3.57
billion, respectively, and are expected to grow4.
A large proportion of this burden is caused by incorrect
or late diagnosis and treatment of BD and MDD5, and
could be significantly reduced by means of early inter-
ventions4. Although BD can be distinguished from MDD
by the intermittent occurrence of manic (BD I) or hypo-
manic (BD II) episodes, these often remain undiagnosed
as patients are more likely to seek medical help during a
depressive episode6. In turn, because depressive episodes
in BD are indistinguishable from those in MDD, BD is
often misdiagnosed as MDD, even if the depressive
symptoms were preceded by a manic/hypomanic episode.
In fact, ~37% of patients with BD who present after their
first manic/hypomanic episode are nonetheless mis-
diagnosed as having MDD7. Overall, it is estimated that at
least 19% of individuals experiencing a major depressive
episode have BD8, and that ~40% of patients with BD are
initially diagnosed with MDD7,9, with the average delay in
BD diagnosis ranging from 5.7 to 7.5 years10,11. As a
result, misdiagnosed patients with BD are often incor-
rectly treated with antidepressants, which can aggravate
the disease and worsen the outcomes12.
The correct diagnosis of BD and MDD is further
impeded by the unknown aetiology of these conditions
and the lack of objective diagnostic measures. Diagnosing
BD and MDD relies primarily on assessing patient self-
reported symptoms in accordance to state-of-the-art
diagnostic manuals, such as the Diagnostic and Statis-
tical Manual of Mental Disorders, 5th Edition (DSM-5)13
or the International Statistical Classification of Diseases
and Related Health Problems, 11th Revision (ICD-11)14.
While structured psychiatric interviews are considered a
gold standard for mental health disorder diagnosis, their
systematic use in primary care, where the majority of
MDD diagnoses are made, can be hindered by factors
such as availability of qualified staff, inter-rater variability
and time constraints15. In this regard, digital platforms
offer a promising alternative for collecting and evaluating
patient mental health data, while offering the advantage of
being more easily available, adaptable, scalable and cost-
effective compared to traditional, interview-based
methods16. Existing digital mental health applications
are generally considered safe17, although, despite their
rapidly growing numbers, little evidence is available on
their accuracy or efficacy16. Furthermore, it is anticipated
that diagnostic accuracy in mental healthcare can be
improved by incorporating biomarker profiling strategies,
which could additionally provide a biological basis for
mood disorder stratification and personalised treatment18.
We aimed to establish and validate a diagnostic algo-
rithm, based on a new online mental health questionnaire
and blood biomarker data, to detect BD in patients with a
recent diagnosis of MDD and, hence, reduce the mis-
diagnosis of BD as MDD.
Materials and methods
Study design and participants
Data analysed here were collected as part of the Delta
Study, an investigator-led study conducted by the Cam-
bridge Centre for Neuropsychiatric Research (CCNR) at
the University of Cambridge, which aimed to improve
mood disorder diagnosis in participants presenting with
depressive symptoms19–22. The primary objective of the
Delta Study was to identify BD patients among patients
who have recently (≤5 years)10,11 been diagnosed as hav-
ing MDD. The study was approved by the University of
Cambridge Human Biology Research Ethics Committee
(approval number HBREC 2017.11) and was conducted in
compliance with the Declaration of Helsinki23, Good
Clinical Practice and ISO 14155:2011. A detailed research
protocol for the Delta Study has been published pre-
viously19. Participants were recruited online through
email, via the CCNR website and Facebook. Inclusion
criteria for the study required participants to be between
18 and 45 years old, residents of the United Kingdom, at
least mildly depressed (Patient Health Questionnaire-924
total score ≥5), not pregnant or breastfeeding, and not
suicidal. All participants read the participant information
sheet and digitally provided informed consent for parti-
cipation in the study. Recruitment started on 27 April
2018 and was completed on 28 September 2018. The
current work complies with the Standards for Reporting
of Diagnostic Accuracy Studies (STARD)25 and the
Strengthening the Reporting of Observational Studies in
Epidemiology (STROBE)26 guidelines.
Procedures
Upon enrolment, participants were asked to complete a
purpose-built online mental health questionnaire avail-
able through the Delta Study website. The questionnaire
was developed in collaboration with experienced psy-
chiatrists and a service user advisory group and was based
on existing structured diagnostic interviews as well as a
range of mental health screening questionnaires19. It
consisted of 635 distinct questions belonging to 6
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modules: (1) demographic information, (2) manic and
hypomanic symptoms, (3) depressive symptoms, (4) per-
sonality traits, (5) psychiatric history and (6) other psy-
chiatric conditions. The questionnaire was adaptive to
answers given by participants, so that only relevant
questions were asked, and the maximum possible number
of questions asked to an individual was 382 (284 on
average). Data collected from the questionnaire were used
to identify participants qualifying for the study objectives,
and as independent variables in statistical modelling.
Next, eligible participants who consented to providing a
blood sample and completing a telephone diagnostic
interview, who were free from blood-borne illnesses and
had no previous diagnosis of schizophrenia, were pro-
vided with a dried blood spot (DBS) collection kit by post.
The kit was designed to allow minimally invasive blood
sample collection in a non-clinical setting, and was a
Conformité Européenne-marked device under Article 22
of the Medical Device Regulation 2017/745. The kit
included pre-injection cleaning swabs, sterile finger prick
lancets, a DBS collection card (226 Spot Saver Cards,
PerkinElmer), adhesive plasters and cotton pads. Detailed
instructions for DBS sample collection were provided in a
leaflet and as an online video. Participants were asked to
spot 5 separate DBSs onto the card, after at least 6 h of
fasting, and allow the card to dry for a minimum of 3 hrs
at room temperature. Cards were subsequently placed in
the provided resealable bags with desiccant, and returned
by post using pre-paid envelopes.
The returned DBS samples were analysed for neu-
ropsychiatric biomarker levels using a validated targeted
proteomic approach27–29. The method targeted 203
unique peptides representing 120 proteins (Supplemen-
tary Table 1) selected based on their association with
psychiatric conditions and concentration in the blood28.
DBS samples were processed using an automated Biomek
NX workstation (Beckman Coulter). Proteins were
extracted from 3mm DBS discs using 50mM ammonium
bicarbonate, followed by disulphide bond reduction with
5 mM dithiothreitol and cysteine alkylation using 10mM
iodoacetamide. Next, proteins were digested overnight
with trypsin at 1:20 enzyme to protein ratio, followed by
peptide purification in FNSC18 plates (Glygen Corp.) and
elution with 60% acetonitrile. Stable isotope-labelled
internal standard (SIS) peptides were subsequently
spiked in for each target peptide to enable quantitative
analysis. Infinity 1290 liquid chromatography system
(Agilent) was used to separate ~3.2 µg of digested proteins
on a 2.1 × 150 mm AdvanceBio Peptide Mapping column
(Agilent) at 50 °C. Peptides were eluted using a gradient of
acetonitrile in 0.1% formic acid from 3 to 30% over
45minutes at 0.3 ml/min, and analysed with a triple
quadrupole mass spectrometer model 6495 (Agilent)
equipped with a Jet Stream ion source operated in positive
ionisation mode, using dynamic multiple reaction mon-
itoring27. Samples were randomised across plates, plate
positions and experimental days to minimise technical
bias, and quality control samples were included to
monitor variation in sample preparation and instrument
performance. Experimenters were blind to sample diag-
nostic allocation.
Outcomes
Participants who successfully completed the online
questionnaire and returned the DBS sample were invited
to complete the World Health Organization World
Mental Health Composite International Diagnostic
Interview (CIDI), version 3.030 via telephone. The CIDI is
a modular diagnostic tool which is widely used in epide-
miological studies on mental health31 and shows good
concordance with structured diagnostic interviews con-
ducted by clinicians32. All interviewers conducting the
CIDI received in-person training from an external CIDI-
certified instructor, and internal training and mentoring.
Only modules of the CIDI required for the lifetime mood
disorder diagnosis, i.e. the screening, depression and
mania sections, were implemented. We adopted voluntary
response sampling, whereby the CIDI interviews con-
tinued until pre-specified study recruitment targets
were met.
Statistical analysis
Power calculations for the study’s primary objective
showed that, assuming at least 80% sensitivity of the
algorithm in detecting BD previously diagnosed as MDD
and at least a 20% prevalence of BD among participants
recently diagnosed with MDD8, a minimum of 200 par-
ticipants with a recent diagnosis of MDD by a medical
professional were required to provide at least 80% power
to detect model noninferiority against an AUROC of 0.80
at the 5% significance level. The required number of
participants was increased to 300 to account for potential
dropouts, as observed in previous studies. Analogous
calculations demonstrated that at least 300 symptomatic
participants with no baseline diagnosis of mood disorder
were required for the study’s secondary objectives19.
Additionally, we aimed to recruit 40 participants with a
previous diagnosis of BD by a medical professional to
validate the algorithm.
Data processing and analysis were conducted in R ver-
sion 3.6.333. The online mental health questionnaire data
were restructured so that answers to equivalent questions
were concatenated (e.g. current and past symptoms),
missing values were imputed where feasible (e.g. the
number of relatives with depression was set to 0 for
participants with no family history of mental health
conditions), and features derived from the original vari-
ables were added (guided by the design of existing
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diagnostic algorithms, e.g. the number of symptoms).
Ordinal questionnaire data were converted to ranks, and
categorical data were encoded as dummy variables. Fea-
tures that were duplicated, bijections or constant were
removed. All missing values in the dataset were due to the
adaptive character of the questionnaire (missing not at
random and more likely for MDD). Raw biomarker data
were processed in Skyline version 3.1.034. Peptides which
were not detected (N= 9) were excluded from the ana-
lyses. Relative biomarker quantification was based on the
ratios of abundances of the endogenous peptides over the
abundances of the corresponding SIS peptides. Potential
batch effects, caused by processing and analysing DBS
samples across multiple plates, were adjusted for by
median scaling. Biomarker level values were log2-trans-
formed prior to analysis. The final number of analysed
features was 1151, including 957 items from the online
mental health questionnaire and 194 protein peptide
measurements. The CIDI diagnosis was used as the
dependent variable.
The diagnostic algorithm was trained and validated
using data from participants with a recent self-reported
diagnosis of MDD, confirmed as MDD or changed to BD
by the CIDI. Participants whose DBS samples were not
usable, or whose answers to the screening question about
elevated mood on the online questionnaire and the tele-
phone interview were inconsistent, were excluded (Fig. 1).
Extreme Gradient Boosting (XGBoost)35, a decision tree-
based machine learning method, was selected to build the
diagnostic algorithm, primarily because of its ability to
handle missing values and detect non-linear relationships
and interactions between variables, being robust to cor-
related features, as well as its interpretability. Nested
cross-validation (CV), an equivalent to creating multiple
train-test splits, was used to obtain robust estimates of
model predictive performance in previously unseen
data36. We used 5-fold stratified nested CV, wherein at
each iteration 4 of the folds were used in the inner loop to
tune model parameters and train the algorithm, and the
5th fold was used in the outer loop to test the trained
model. Training of the XGBoost model was based on 5-
fold stratified CV repeated three times. Tuned model
parameters included the number of trees (1 to 100), tree
depth (1 or 2, to allow for first order interactions) and the
learning rate (0.1 or 0.3). Initial testing showed that more
extensive tuning was not required. Model performance
was evaluated using AUROC. To avoid overfitting, opti-
mal model parameters were defined as those which
resulted in the simplest model with AUROC within
1 standard error below the AUROC of the best per-
forming model. The final model was fitted using the tuned
parameters to all data from the inner loop, and evaluated
on the test set in the outer loop. Youden’s J statistic37 was
used to determine the optimal classification cut-off with
balanced sensitivity and specificity. Nested CV was repe-
ated 20 times, resulting in 100 models. The 95% con-
fidence intervals (CI) were estimated for all measures of
diagnostic performance as the 2.5th and 97.5th percentiles
across the 100 models. Features were evaluated based on
their occurrence frequency across the 100 models and
mean feature importance, i.e. gain (increase in accuracy
brought by a feature to the branches it occurred on). The
directionality of the relationship between the predictor
and outcome variables was determined using the SHapley
Additive exPlanations (SHAP) method38. The trained
models were additionally validated in symptomatic par-
ticipants with no previous diagnosis of mood disorder,
and in participants with a previously established diagnosis
of BD. Additional analyses included training classification
models using: (1) subsamples of the training data, to
assess potential bias related to sample size39; (2) only
features from the online questionnaire or only the bio-
marker data, to separately assess their potential utility;
and (3) all available instances, i.e. including participants
whose answers were inconsistent between the online and
telephone assessments, to assess selection bias.
Results
The study flow diagram is shown in Fig. 1. To achieve
study recruitment targets, 5422 symptomatic individuals
were enrolled, of which 3232 completed the online mental
health questionnaire, 1377 provided a DBS sample and
924 completed the CIDI diagnostic interview. The average
time interval between starting the online assessment and
completing the CIDI interview was 14 days. Only data
from participants who returned a usable DBS sample and
whose answers on the online questionnaire and the tele-
phone interview were not inconsistent were analysed
(N= 688; Fig. 1). These included 126 participants with BD
(N= 76 BD I and 50 BD II) diagnosed as MDD and 187
participants with confirmed MDD from the primary
dataset, and 98 newly diagnosed participants with BD
(N= 60 BD I and 38 BD II), 112 newly diagnosed parti-
cipants with MDD, 120 participants with subclinical low
mood (i.e. no previous mood disorder diagnosis and no
mood disorder diagnosis from the CIDI), and 45 partici-
pants with a previous diagnosis of BD from the secondary
datasets (Fig. 1). Demographic and clinical characteristics
are shown in Table 1. Participants with BD who had been
diagnosed as having MDD were, on average ± standard
deviation (SD), 27.4 ± 7.2 years old, 59% female, and
overweight (BMI of 28.5 ± 7.4). The mean duration of
MDD diagnosis in this group was 2.7 ± 1.6 years. The
majority (94%) had been treated with antidepressant
medication, and the same percentage had never received
any mood stabiliser treatment. Previous self-reported
MDD diagnoses were made primarily by a General
Practitioner (81.2%), followed by those made by a
Tomasik et al. Translational Psychiatry           (2021) 11:41 Page 4 of 12
psychiatrist (18.5%) and other medical professionals
(0.3%). Of the 45 participants with previously diagnosed
BD, 35 (78%) reported having been initially diagnosed
with MDD, with the average time between MDD and BD
diagnosis in this group being 5.5 ± 5.9 years. The mean
duration of existing BD diagnosis was 7.5 ± 6.8 years.
The trained algorithms showed an out-of-fold AUROC
of 0.92 (95% CI: 0.86–0.97) in separating participants with
BD previously diagnosed as MDD from those with con-
firmed MDD (Fig. 2A). In subgroup analyses, the AUROC
was higher in participants with BD I (0.94; 0.88–0.98) than
in participants with BD II (0.88; 0.78–0.95). The out-of-
fold area under the precision-recall curve (AUPRC) in the
primary dataset was 0.85 (0.73–0.95; Fig. 2B). Detailed
estimates of out-of-fold model performance are sum-
marised in Table 2.
The median number of features across the models was
9, with the interquartile range between 6 and 15. Perfor-
mance was driven primarily by the 5 features present in
the majority of the models, namely elevated mood,
grandiose delusions, talkativeness, recklessness, and risky
behaviour (Table 3). Among the 30 most frequently
selected features, 26 were from the online questionnaire,
including questions on mania/hypomania, emotional
instability, psychiatric history and comorbidities, and
quality of life, and four were biomarker measurements.
Directionality of the relationships is shown in Supple-
mentary Fig. 1. Follow-up analyses showed that models
built using the online questionnaire or blood biomarker
data separately had respective AUROCs of 0.92 (95% CI:
0.85–0.97) and 0.50 (0.34–0.62). Details of the models
trained using only the online questionnaire data or the
biomarker data are shown is Supplementary Tables 2–5.
Additional validation in the secondary datasets showed
that the models separated participants with newly diag-
nosed BD from those with newly diagnosed MDD and
subclinical low mood with respective AUROCs of 0.89
(95% CI: 0.86–0.91) and 0.90 (0.87–0.91), and AUPRCs of
0.87 (0.81–0.90) and 0.84 (0.80–0.88; Fig. 2C–F and Table
2). Furthermore, the models predicted the correct diag-
nosis in 86% (57–96%) of participants with an established
diagnosis of BD (Table 2).
Sensitivity analyses showed that the study was sufficiently
powered, as indicated by the plateauing model performance
at training set sizes ≥100 (Supplementary Figs. 2 and 3). An
additional analysis indicated that some selection bias might
have been introduced when excluding participants who gave
inconsistent answers on the online and telephone assess-
ments. Including those participants in the analysis returned a
test AUROC of 0.86 (95% CI: 0.78–0.93) when distinguishing
participants with BD previously diagnosed as MDD from
those with confirmed MDD.
Fig. 1 Delta Study flow diagram. The diagram shows the number of individuals who completed each step of the study and reasons for attrition.
BD bipolar disorder, DBS dried blood spot, MDD major depressive disorder, WHO WMH-CIDI World Health Organization World Mental Health
Composite International Diagnostic Interview.
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Table 1 Demographic and clinical characteristics of study participants.
Baseline MDD Baseline low mood Baseline BD
Diagnosis BD MDD BD MDD Low mood BD P value
N 126 187 98 112 120 45 NA
Age, mean (SD), years 27.4 (7.2) 28.1 (6.9) 25.4 (5.9) 26.4 (6.2) 25.8 (6.5) 33.9 (7.8) <0.001
Sex, N (%)
Male 52 (41) 50 (27) 36 (37) 30 (27) 40 (33) 28 (62) <0.001
Female 74 (59) 137 (73) 62 (63) 82 (73) 80 (67) 17 (38)
BMI, mean (SD), kg/m2 28.5 (7.4) 28.3 (7.0) 26.3 (6.6) 26.6 (6.6) 24.6 (4.5) 28.6 (6.2) <0.001
Ethnicity, N (%)
Asian/British Asian 1 (1) 3 (2) 2 (2) 1 (1) 7 (6) 0 (0) 0.104
Black/Black British 1 (1) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
White 93 (74) 132 (71) 61 (62) 74 (66) 73 (61) 37 (82)
Mixed 5 (4) 5 (3) 3 (3) 5 (4) 3 (3) 0 (0)
Other 0 (0) 1 (1) 1 (1) 2 (2) 4 (3) 0 (0)
Prefer not to say 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Unknowna 26 (21) 46 (25) 31 (32) 30 (27) 33 (28) 8 (18)
Smoking, N (%)
No 40 (32) 116 (62) 36 (37) 60 (54) 67 (56) 18 (40) <0.001
Yes 86 (68) 71 (38) 62 (63) 52 (46) 53 (44) 27 (60)
Alcohol consumption, N (%)
No 36 (29) 45 (24) 19 (19) 16 (14) 14 (12) 16 (36) 0.001
Yes 90 (71) 142 (76) 79 (81) 96 (86) 106 (88) 29 (64)
Recreational drug use, N (%)
No 71 (56) 131 (70) 41 (42) 69 (62) 71 (59) 33 (73) <0.001
Yes 55 (44) 56 (30) 57 (58) 43 (38) 49 (41) 12 (27)
Education, N (%)
<GCSE 3 (2) 0 (0) 4 (4) 2 (2) 1 (1) 0 (0) 0.001
GCSE 18 (14) 19 (10) 8 (8) 5 (4) 10 (8) 8 (18)
A-level 49 (39) 46 (25) 33 (34) 23 (21) 32 (27) 12 (27)
Undergraduate degree 37 (29) 79 (42) 33 (34) 48 (43) 57 (48) 19 (42)
Postgraduate degree 19 (15) 43 (23) 20 (20) 34 (30) 20 (17) 6 (13)
Employment, N (%)
Employed/self-employed 81 (64) 111 (59) 62 (63) 68 (61) 68 (57) 22 (49) <0.001
Parental leave 0 (0) 1 (1) 0 (0) 0 (0) 0 (0) 0 (0)
Student 28 (22) 50 (27) 22 (22) 37 (33) 47 (39) 9 (20)
Retired 0 (0) 1 (1) 0 (0) 0 (0) 0 (0) 2 (4)
Unemployed 17 (13) 24 (13) 14 (14) 7 (6) 5 (4) 12 (27)
Relationship status, N (%)
In a relationship 80 (63) 114 (61) 57 (58) 81 (72) 81 (68) 30 (67) 0.275
Single 46 (37) 73 (39) 41 (42) 31 (28) 39 (32) 15 (33)
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Discussion
The main aim of the present study was to develop a
diagnostic algorithm, based on an online mental health
questionnaire and blood biomarker data, to identify BD
patients among recently diagnosed MDD patients. The
trained models achieved an average test AUROC of 0.92,
with a mean accuracy of 0.83, representing a 38%
improvement compared to the baseline accuracy of 0.60,
i.e. the proportion of correctly diagnosed patients with
MDD in the primary dataset (187/313). While we pre-
specified the AUROC threshold for clinical relevance at
0.8019, the obtained estimate of above 0.90 is considered
‘excellent’40 or ‘almost perfect’32 for mental health dis-
order diagnosis. The remaining discrepancy between the
algorithm and the CIDI outcomes is not unexpected given
general diagnostic uncertainty surrounding psychiatric
conditions, whereby even the ‘gold standard’ measures
disagree in a small number of cases41.
The present results confirmed self-reported elevated
mood, grandiosity, talkativeness, and recklessness as core
Table 1 continued
Baseline MDD Baseline low mood Baseline BD
Diagnosis BD MDD BD MDD Low mood BD P value
Childhood trauma, N (%)
No 44 (35) 84 (45) 32 (33) 55 (49) 77 (64) 15 (33) <0.001
Yes 81 (64) 102 (55) 65 (66) 53 (47) 39 (32) 29 (64)
Prefer not to say 1 (1) 1 (1) 1 (1) 4 (4) 4 (3) 1 (2)
Family psychiatric history, N (%)
No 27 (21) 31 (17) 27 (28) 38 (34) 41 (34) 2 (4) <0.001
Yes 99 (79) 156 (83) 71 (72) 74 (66) 79 (66) 43 (96)
Duration of MDD diagnosis, mean (SD), years 2.7 (1.6) 2.6 (1.5) NA NA NA 5.5 (5.9)b 0.037
Antidepressant treatment, N (%)
SSRI 116 (92) 174 (93) 27 (28) 16 (14) 14 (12) 38 (84) <0.001
SNRI 24 (19) 22 (12) 2 (2) 2 (2) 1 (1) 20 (44)
TCA 13 (10) 19 (10) 6 (6) 2 (2) 1 (1) 16 (36)
Other 15 (12) 17 (9) 3 (3) 3 (3) 2 (2) 8 (18)
None 7 (6) 9 (5) 67 (68) 91 (81) 104 (87) 5 (11)
Duration of BD diagnosis, mean (SD), years NA NA NA NA NA 7.5 (6.8) NA
Mood stabiliser treatment, N (%)
No 119 (94) 180 (96) 97 (99) 112 (100) 120 (100) 18 (40) <0.001
Yes 7 (6) 7 (4) 1 (1) 0 (0) 0 (0) 27 (60)
Psychiatric hospitalisation, N (%)
No 105 (83) 170 (91) 91 (93) 111 (99) 119 (99) 25 (56) <0.001
Yes 21 (17) 17 (9) 7 (7) 1 (1) 1 (1) 20 (44)
PHQ-9 score, mean (SD) 16.2 (4.7) 13.8 (4.8) 14.3 (4.7) 12.9 (4.7) 9.9 (3.7) 13.1 (4.4) <0.001
WEMWBS score, mean (SD) 33.0 (7.5) 35.1 (7.3) 35.2 (7.4) 36.8 (7.3) 42.0 (7.0) 36.5 (6.7) <0.001
Fasting at DBS collection
No 2 (2) 1 (1) 4 (4) 0 (0) 2 (2) 2 (4) 0.097
Yes 124 (98) 186 (99) 94 (96) 112 (100) 118 (98) 43 (96)
P values were obtained from the Kruskal–Wallis test for continuous variables and χ2 test for categorical variables.
BD bipolar disorder, BMI body mass index, DBS dried blood spot, GCSC General Certificate of Secondary Education, MDD major depressive disorder, NA not applicable,
PHQ-9 Patient Health Questionnaire-9, SD standard deviation, SNRI serotonin-norepinephrine reuptake inhibitor, SSRI selective serotonin reuptake inhibitor, TCA
tricyclic antidepressant. WEMWBS Warwick-Edinburgh Mental Wellbeing Scale.
aInformation on ethnicity was collected at 6 months follow-up, which was not completed by all participants.
bUntil BD diagnosis (N= 35).
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AUROC 0.92
(95% CI: 0.86-0.97)
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Fig. 2 Receiver operating characteristic and precision-recall curves for prediction of bipolar disorder diagnosis. A, B Out-of-fold results of
nested cross-validation in the primary dataset (N= 126 BD previously diagnosed as MDD vs. N= 187 confirmed MDD). Thick lines represent curves
calculated from probabilities averaged across all models. C–F Validation in baseline low mood group (N= 98 newly diagnosed BD vs. N= 112 newly
diagnosed MDD (C, D) and vs. N= 120 with subclinical depressive symptoms (E, F)). AUROC and AUPRC values represent mean (95% CI). AUPRC area
under the precision-recall curve, AUROC area under the receiver operating characteristic curve, BD bipolar disorder, CI confidence intervals, MDD
major depressive disorder.
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features of BD. Therefore, it is feasible that a simple, low-
cost and highly scalable digital self-reporting tool could
help expedite a correct diagnosis of BD by early capturing
of emerging symptoms in patients presenting with
depressive symptoms. The adaptive design of the ques-
tionnaire could be further streamlined by applying itera-
tive machine learning algorithms, such as Bayesian
updating or reinforcement learning, to offer dynamic
question selection personalised to individual users.
However, this approach would require a substantially
larger training set size and limit the amount of user data
available for future exploratory analyses. Introducing such
digital instruments into primary healthcare, where
resources are scarce and where symptoms of BD often
remain undiagnosed42, has the potential to lessen the
burden experienced by both patients and medical pro-
fessionals, and therefore reduce the overall load on the
healthcare system. In particular, such an approach could
constitute a cost- and time-effective alternative to con-
ventional, interview-based methods, while allowing for a
more comprehensive symptom assessment and identifi-
cation of patients who require specialty care services early
in the mental health triage process.
In addition, among the top ranked predictors were more
objective features such as symptoms reported as being
‘observed by others’ concerning risky behaviour and speaking
faster, the number of second-degree relatives with MDD,
sleep disturbances, and several biomarkers including
kininogen-1 (KNG1) and thrombospondin-1 (TSP1), pro-
teins previously reported to discriminate BD from MDD43,44.
Although biomarker data alone were not predictive of the
disease status, their selection alongside digital features in
some models suggests their potential utility in subgroups of
patients or in specific symptom contexts. All together, these
results indicate the emerging potential for more objective
and systematic diagnostic approaches, such as digital
phenotyping of symptoms45, multi-reporter assessment sys-
tems46, and genetic47 and proteomic44,48 biomarker profiling,
in aiding the diagnosis of BD.
This study has a number of advantages compared to
previous studies aiming to distinguish BD from MDD
during depressive episodes. To our knowledge it is the
largest investigation, with more than twice as many par-
ticipants as the largest study to date (N= 313 vs. N=
112)44. It has also been more extensively validated,
through the application of nested CV in the primary
dataset and additional testing in two secondary datasets,
while previous studies employed 10-fold or leave-one-out
CV and no external test sets. Although not directly
comparable, the algorithm outperformed existing models,
for which the maximum AUROC was 0.905849. The
current study is also unique in its aim to develop a robust
heuristic algorithm to detect BD in individuals with a
recent diagnosis of MDD based on combined symptom
and biomarker data.
The present results should be interpreted within their
limitations. Due to recruiting participants through the
internet, and in order to meet specific study recruitment
targets, the analysed population might be biased and not
representative of patients presenting in primary or sec-
ondary care services. In addition, we did not have access
to participants’ medical records and could not verify the
self-reported psychiatric history. Also, despite attempting
to control for the consistency of answers between the
online and telephone assessments, other inaccuracies
might have remained in the dataset. It is also important to
note that such step would be unfeasible in real-life
applications, and alternative approaches, built into the
online questionnaire, should be employed to protect data
integrity50. Finally, BD might have not been detected in
participants who have not yet experienced a manic/
hypomanic episode, and a longitudinal study would be
Table 2 Out-of-fold model performance in the primary and secondary datasets.
Baseline MDD Baseline low mood Baseline BD
126 BD vs. 187 MDD 98 BD vs. 112 MDD 98 BD vs. 120 low mood 45 BD
AUROC 0.92 (0.86–0.97) 0.89 (0.86–0.91) 0.90 (0.87–0.91) NA
AUPRC 0.85 (0.73–0.95) 0.87 (0.81–0.90) 0.84 (0.80–0.88) NA
Accuracy 0.83 (0.76–0.91) 0.80 (0.75–0.84) 0.82 (0.77–0.86) NA
Sensitivity 0.84 (0.66–1.00) 0.77 (0.61–0.90) 0.77 (0.61–0.90) 0.86 (0.57–0.96)
Specificity 0.83 (0.65–0.95) 0.83 (0.76–0.92) 0.86 (0.77–0.94) NA
PPV 0.77 (0.64–0.91) 0.80 (0.76–0.88) 0.83 (0.76–0.89) NA
NPV 0.89 (0.79–1.00) 0.81 (0.72–0.90) 0.83 (0.74–0.91) NA
Values are shown as mean (95% confidence intervals).
AUPRC area under the precision-recall curve, AUROC area under the receiver operating characteristic curve, BD bipolar disorder, MDD major depressive disorder, NA
not applicable, NPV negative predictive value, PPV positive predictive value.
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required to determine the correct diagnosis for those
individuals.
In conclusion, our study provides a proof of concept
that an evidence-based algorithm can accurately detect
BD in patients recently diagnosed with MDD. The results
may generalise to other clinically relevant populations.
Further work is required to rigorously assess the potential
of incorporating such algorithms into primary healthcare,
where the majority of MDD diagnoses are made, to
expedite the diagnosis of BD and reduce workload for
healthcare professionals.
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Table 3 Top predictors of bipolar disorder.
Feature Frequency Importance, mean (SD) Category
Elevated mood 0.99 0.182 (0.080) Bipolar/hypomania
Grandiosity 0.87 0.095 (0.042) Bipolar/hypomania
More talkative 0.82 0.193 (0.089) Bipolar/hypomania
Recklessness (HMQ) 0.82 0.122 (0.087) Bipolar/hypomania
Others: risky behaviour 0.77 0.232 (0.122) Bipolar/hypomania
Others: speaking faster 0.38 0.033 (0.018) Bipolar/hypomania
Recklessness (PQ) 0.38 0.041 (0.016) Emotional instability
Increased energy 0.37 0.055 (0.030) Bipolar/hypomania
Mood lability 0.35 0.037 (0.013) Emotional instability
Risky behaviour 0.31 0.225 (0.125) Bipolar/hypomania
Episode duration 0.30 0.050 (0.021) Bipolar/hypomania
≥3 symptoms 0.30 0.143 (0.099) Bipolar/hypomania
Second-degree relatives with MDD 0.27 0.030 (0.014) History/comorbidities
Past elevated mood 0.25 0.025 (0.009) Bipolar/hypomania
Fear of abandonment 0.22 0.031 (0.013) Emotional instability
Number of episodes 0.21 0.050 (0.021) Bipolar/hypomania
Self-image instability 0.18 0.034 (0.014) Emotional instability
Racing thoughts 0.14 0.065 (0.045) Bipolar/hypomania
Feeling loved (2 weeks) 0.14 0.022 (0.008) Quality of life
KNG1 (YFIDFVAR) 0.12 0.022 (0.008) Biomarker
Unstable relationships 0.12 0.023 (0.006) Emotional instability
IGHG1 (FNWYVDGVEVHNAK) 0.11 0.014 (0.005) Biomarker
Recklessness (BDQ) 0.10 0.040 (0.016) Bipolar/hypomania
Functional impairment/Hospitalisation 0.09 0.055 (0.031) Bipolar/hypomania
TSP1 (GTLLALER) 0.09 0.015 (0.007) Biomarker
Social activity 0.08 0.031 (0.023) Bipolar/hypomania
APOA1 (ATEHLSTLSEK) 0.07 0.008 (0.008) Biomarker
Productivity 0.07 0.017 (0.008) Bipolar/hypomania
Sleep distress 0.07 0.004 (0.003) History/comorbidities
Duration of social phobia 0.07 0.010 (0.004) History/comorbidities
Table shows 30 most frequently selected features and their importance (i.e. gain). Biomarkers are labelled as ‘UniProtKB protein ID (target peptide sequence)’.
APOA1 apolipoprotein A1, BDQ bipolar disorder questionnaire, HMQ hypomania questionnaire, IGHG1 immunoglobulin heavy constant gamma 1, KNG1 kininogen 1,
MDD major depressive disorder, PQ personality disorder questionnaire, SD standard deviation, TSP1 thrombospondin-1, UniProtKB UniProt Knowledgebase.
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